Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and lowers the price target from $124 to $119.
Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and lowers the price target from $124 to $119.